Revenue Insights: Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc. Performance Compared

Biopharma Revenue Growth: Vertex vs. ACADIA

__timestampACADIA Pharmaceuticals Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014120000580415000
Thursday, January 1, 2015610001032336000
Friday, January 1, 2016173310001702177000
Sunday, January 1, 20171249010002488652000
Monday, January 1, 20182238070003047597000
Tuesday, January 1, 20193390760004162821000
Wednesday, January 1, 20204417550006205683000
Friday, January 1, 20214841450007574400000
Saturday, January 1, 20225172350008930700000
Sunday, January 1, 20237264370009869200000
Monday, January 1, 202411020100000
Loading chart...

Unleashing the power of data

Revenue Growth: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, Vertex Pharmaceuticals Incorporated and ACADIA Pharmaceuticals Inc. have showcased distinct revenue trajectories over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has demonstrated a robust growth, with revenues surging from approximately $580 million to nearly $9.9 billion, marking an impressive 1,600% increase. This growth underscores Vertex's strategic advancements in the treatment of cystic fibrosis and other rare diseases.

Conversely, ACADIA Pharmaceuticals, while starting from a modest base, has also shown significant progress. Its revenue grew from a mere $61,000 in 2015 to over $726 million in 2023, reflecting a remarkable 11,900-fold increase. This leap highlights ACADIA's successful expansion in the neurological disorder market.

These trends not only reflect the companies' strategic focus but also the broader industry's shift towards specialized therapies, promising a dynamic future for both firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025